These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 24173357)
1. Semicarbazide-sensitive amine oxidase and kidney disease. Wong MY; Saad S; Pollock C; Wong MG Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1637-44. PubMed ID: 24173357 [TBL] [Abstract][Full Text] [Related]
2. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Katagiri D; Hamasaki Y; Doi K; Negishi K; Sugaya T; Nangaku M; Noiri E Kidney Int; 2016 Feb; 89(2):374-85. PubMed ID: 26535996 [TBL] [Abstract][Full Text] [Related]
3. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet. Yu PH; Wang M; Deng YL; Fan H; Shira-Bock L Diabetologia; 2002 Sep; 45(9):1255-62. PubMed ID: 12242458 [TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. O'Rourke AM; Wang EY; Miller A; Podar EM; Scheyhing K; Huang L; Kessler C; Gao H; Ton-Nu HT; Macdonald MT; Jones DS; Linnik MD J Pharmacol Exp Ther; 2008 Feb; 324(2):867-75. PubMed ID: 17993604 [TBL] [Abstract][Full Text] [Related]
6. Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy. Wong MY; Saad S; Wong MG; Stangenberg S; Jarolimek W; Schilter H; Zaky A; Gill A; Pollock C PLoS One; 2020; 15(6):e0234617. PubMed ID: 32555665 [TBL] [Abstract][Full Text] [Related]
7. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Boomsma F; de Kam PJ; Tjeerdsma G; van den Meiracker AH; van Veldhuisen DJ Eur Heart J; 2000 Nov; 21(22):1859-63. PubMed ID: 11052858 [TBL] [Abstract][Full Text] [Related]
8. [The role of tubulointerstitial changes in progression of kidney function failure in patients with chronic glomerulonephritis (GN)]. Idasiak-Piechocka I; Krzymański M Przegl Lek; 1996; 53(5):443-53. PubMed ID: 8754411 [TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. Salter-Cid LM; Wang E; O'Rourke AM; Miller A; Gao H; Huang L; Garcia A; Linnik MD J Pharmacol Exp Ther; 2005 Nov; 315(2):553-62. PubMed ID: 16081681 [TBL] [Abstract][Full Text] [Related]
10. Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do. O'Sullivan J; Unzeta M; Healy J; O'Sullivan MI; Davey G; Tipton KF Neurotoxicology; 2004 Jan; 25(1-2):303-15. PubMed ID: 14697905 [TBL] [Abstract][Full Text] [Related]
12. The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its components. Alpert MA; Govindarajan G; Del Rosario ML; Reisin E J Cardiometab Syndr; 2009; 4(1):57-62. PubMed ID: 19245518 [TBL] [Abstract][Full Text] [Related]
13. Semicarbazide-sensitive amine oxidase: role in the vasculature and vasodilation after in situ inhibition. Vidrio H Auton Autacoid Pharmacol; 2003; 23(5-6):275-83. PubMed ID: 15255812 [TBL] [Abstract][Full Text] [Related]
14. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Brewster UC; Perazella MA Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655 [TBL] [Abstract][Full Text] [Related]
15. [Reversal of renal fibrosis: lessons from experimental models]. Dussaule JC; Chatziantoniou C Bull Acad Natl Med; 2008 May; 192(5):987-1000; discussion 1000-1. PubMed ID: 19238788 [TBL] [Abstract][Full Text] [Related]